MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
There were some major upsets in the trends hierarchy in March, but not at the top where Medtronic (NYSE:MDT) continues to reign as the most talked-about and searched-for medtech company around. The titan was the subject of a slew of headlines, including rumors of the company’s involvement with an orgasm stimulation implant and the highly anticipated outcome of the company’s renal denervation trial.
Covidien (NYSE:COV) jumped to the 2nd-place spot, prompted in part by news that company president & CEO Jose Almeida was tapped as the new chairman of the board for medtech lobbying group AdvaMed. St. Jude Medical (NYSE:STJ) moved up as well, taking 3rd place with news of its ongoing legal war with Volcano (NSDQ:VOLC) and updates on its Nanostim pacemaker.
Boston Scientific (NYSE:BSX) remained in 4th place, releasing updates on its legal activities, tussling with Medtronic and landing regulatory wins in the European Union. GE Healthcare (NYSE:GE) rejoined the top 5, although the company was hit with bad news of a high-risk recall and being named one of the worst-performing medtech makers of the year.
Medtronic
- Medtronic vet takes over marketing at Vexim
- Diabetes: Medtronic teams up with Aetna to tackle Type II diabetes
- Europe spikes Edwards Lifesciences’ TAVI patent in war with Medtronic
- Report: Medtronic signs on to test on-demand orgasm device
- UPDATED: Medtronic denies involvement with on-demand orgasm implant
- Chinese study compares Medtronic spine implants
- Appeals court applies Supreme Court ruling to Medtronic lawsuit against Boston Scientific
- Itamar Medical inks distribution deals with Medtronic, Philips
- AIM: Medtronic, St. Jude recalls illustrate why PMA modifications don’t work
- Medtronic details humanitarian sales to Syria, Cuba, Sudan
- Medtech gears up for Medtronic’s RDN trial results
- Urologix still owes Medtronic $650k
- Medtronic launches cardiac arrest trial for developing nations
- Medtronic can skip FDA panel on positive high-risk CoreValve data
- Medtronic details Symplicity renal denervation data
- Sapien XT bests CoreValve in small head-to-head study
- UPDATE: Reaction to Medtronic’s Symplicity renal denervation data
Covidien
- Covidien touts U.S, European wins for new ventilator
- Covidien’s ev3 seeks new trial in $175M loss to Appriva
- Covidien’s Barrx ablation system stems progression of esophagus disease, study says
- Covidien chief Almeida to chair AdvaMed’s board
St. Jude Medical
- Volcano loses round in FFR war with St. Jude Medical
- St. Jude Medical launches post-approval Nanostim trial in Europe
- Volcano appeals loss to St. Jude Medical in FFR war
- St. Jude’s Prodigy chronic pain Nuristan device lands CE Mark
- St. Jude Medical’s Allure Quadra pacemaker wins FDA OK
- AIM: Medtronic, St. Jude recalls illustrate why PMA modifications don’t work
- St. Jude’s Nanostim pacemaker looks good at 3 months in feasibility study
Boston Scientific
- Boston Scientific legal update: Pelvic mesh looms, Guidant makes progress
- Appeals court applies Supreme Court ruling to Medtronic lawsuit against Boston Scientific
- Boston Scientific lands E.U. approval for Rebel bare-metal stent
- Boston Scientific’s Ingevity MRI-safe cardiac pacing leads win EU nod
- Study shows long-term benefits for some CRT-D patients
GE Healthcare
